[The clinical analysis of haploidentical stem cell transplantation in myelodysplastic syndrome-associated acute myeloid leukemia].

To investigate the prognosis of haploidentical hematopoietic stem cell transplantation (haplo-HSCT) in the treatment of acute myeloid leukemia with myelodysplasia-related changes (AML-MRC). The data of 102 patients with high-risk AML in the first complete remission phase (CR1) who received haplo-HSCT from January 2009 to July 2015 in Peking University People's Hospital were retrospectively analyzed. These 102 cases included 17 AML-MRC cases (AML-MRC group) and 85 other types of AML cases (control group). There were 8 males and 9 females in the AML-MRC group, and the median age was 35 (17-61) years. There were 52 males and 33 females in other high-risk AML group, and the median age was 31 (11-60) years. No difference was observed between the two groups after haploidentical stem cell transplantation in the rates of cytomegalovirus, EBV (Epstein-Barr virus), blood flow infection rate and hematopoietic reconstitution (>0.05). The overall 2-year survival rate after transplantation was 80.8% (95% 51.6%-93.4%) and 72.5% (95% 62.8%-80.1%) (=0.650), the disease-free survival rate was 79.4% (95% 48.8%-92.9%) and 65.9% (95% 54.3%-75.2%) (=0.573), cumulative recurrence rate was 13.0%(95% 1.9%-34.7%) and 13.3%(95% 7.0%-21.5%) (=0.623), and non-relapse mortality was 6.7% (95% 0.3%-27.0%) and 20.0% (95% 12.0%-29.4%) (=0.436). The prognosis of haplo-HSCT in patients with AML-MRC in CR(1) is similar to that of other types of high-risk AML patients. Haplo-HSCT is an ideal choice for patients with AML-MRC in CR(1).